The TMC125-C214 Study Provides Early Access to TMC125 for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens and Will Also Gather Information on the Long-term Safety and Tolerability of TMC125 Combined With Other Antiretroviral Drugs

June 2, 2026 updated by: Tibotec Pharmaceuticals, Ireland

Early Access of TMC125 in Combination With Other Antiretrovirals in Treatment-experienced HIV-1 Infected Subjects With Limited Treatment Options

The purpose of this study is to provide early access of TMC125 to HIV-1 infected patients who have failed multiple antiretroviral (ARV) regimens. Information on safety and tolerability aspects of TMC125 in combination with other ARVs in treatment-experienced HIV-1 patients with limited treatment options will be assessed. Available data regarding the effectiveness of the drug will also be collected. To be eligible, patients should be failing their current ARV regimen or be on a treatment interruption, should have previously received 2 different protease inhibitor (PI) containing regimens and be at least 3-class experienced (protease inhibitors [PI], nucleoside/tide reverse transcriptase inhibitors [N[t]RTIs] and non-nucleoside reverse transcriptase inhibitors [NNRTIs]) or at least 2-class experienced (PIs and N[t]RTIs) with primary NNRTI resistance. TMC125 will be administered in combination with an investigator-selected background of additional ARVs from the list of allowed medications.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Approved for marketing

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

This is an open label trial with primary objective to provide early access to TMC125 for treatment-experienced HIV-1 infected patients who have failed multiple antiretroviral (ARV) regimens and have limited treatment options with currently approved ARVs. The secondary objective of this trial is to gather information on the safety and tolerability aspects of TMC125 in combination with other ARVs. Available efficacy data will also be collected. Patients should be at least 3-class experienced or 2-class experienced with primary non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance. They should also have previously received 2 different protease inhibitor-based regimens (low-dose ritonavir is not counted as a protease inhibitor (PI) regimen), be on a treatment interruption or not be virologically suppressed on their current regimen, and not be able to use currently approved NNRTIs due to resistance (primary or acquired) and/or intolerance. Patients must also meet all in- and exclusion criteria. TMC125 (200mg twice daily) will be provided once the patient has been confirmed eligible for entry. Once treatment with TMC125 in combination with other ARVs has been initiated, patients must be instructed to follow the recommended visit schedule based on routine clinical care. Safety and tolerability of the entire antiretroviral therapy (ART) regimen, including TMC125, should be monitored by the investigator as per standard clinical practice. However, it is recommended that visits be planned 4 and 12 weeks following initiation of TMC125 in combination with other ARVs and every 12 weeks thereafter while on therapy during this trial. Adverse events (AEs) leading to treatment interruption or discontinuation and all serious adverse events (SAEs), with the exception of Acquired Immunodeficiency Syndrome (AIDS) defining illnesses (CDC class C) unless fatal or considered to be related to TMC125, will be collected. Other adverse events will be collected only if required as per local regulations. The background ARVs may be changed at any time during the trial, at the discretion of the investigator due to the development of resistance, intolerance, toxicity, etc. while continuing treatment with TMC125 if in the investigator's assessment the patient still benefits from treatment with TMC125. If changes in the background regimen are made, it is recommended that a follow-up visit be planned 4 weeks after the change in therapy. Treatment with investigational medication will be continued until virologic failure, treatment-limiting toxicity, subject lost to follow-up, patient's withdrawal, pregnancy, discontinuation of TMC125 development or when TMC125 has become commercially available in the patient's country. Patients will be instructed to orally take two 100 mg tablets of TMC125 following a meal every 12 hours. TMC125 (200 mg twice daily) must be used in combination with other antiretroviral drugs. Treatment with investigational medication will continue until virologic failure, treatment-limiting toxicity, patient lost to follow-up, withdrawal, pregnancy, discontinuation of TMC125 development or when TMC125 becomes commercially available in the patient's country.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Expanded Access

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Belgium
      • Antwerp, Belgium
      • Bruges, Belgium
      • Brussels, Belgium
      • Charleroi, Belgium
      • Ghent, Belgium
      • Leuven, Belgium
      • Liège, Belgium
  • Canada
    • Alberta
      • Calgary, Alberta, Canada
      • Edmonton, Alberta, Canada
    • British Columbia
      • Vancouver, British Columbia, Canada
    • Manitoba
      • Winnipeg, Manitoba, Canada
    • New Brunswick
      • Moncton, New Brunswick, Canada
    • Ontario
      • Hamilton, Ontario, Canada
      • Kingston, Ontario, Canada
      • London, Ontario, Canada
      • Ottawa, Ontario, Canada
      • Toronto, Ontario, Canada
      • Whitby, Ontario, Canada
      • Windsor, Ontario, Canada
    • Quebec
      • Montreal, Quebec, Canada
      • Ste-Foy, Quebec, Canada
  • Denmark
      • Aarhus, Denmark
      • Copenhagen, Denmark
      • Hvidovre, Denmark
      • Odense, Denmark
  • Germany
      • Aachen, Germany
      • Berlin, Germany
      • Bochum, Germany
      • Bonn, Germany
      • Cologne, Germany
      • Düsseldorf, Germany
      • Erlangen, Germany
      • Essen, Germany
      • Frankfurt, Germany
      • Freiburg im Breisgau, Germany
      • Hamburg, Germany
      • Hanover, Germany
      • Koblenz, Germany
      • Mainz, Germany
      • Mannheim, Germany
      • Munich, Germany
      • München, Germany
      • Münster, Germany
      • Osnabrück, Germany
      • Stuttgart, Germany
      • Würzburg, Germany
  • Greece
      • Athens, Greece
      • Pátrai, Greece
      • Thessalonikis, Greece
  • Luxembourg
      • Luxembourg, Luxembourg
  • Mexico
      • Bosques Del Nogalar San Nicola, Mexico
      • Chihuahua City, Mexico
      • Col Tacuba, Mexico
      • Guadalajara, Mexico
      • León, Mexico
      • Mexico City, Mexico
      • Monterrey Nuevo León, Mexico
      • Oaxaca City, Mexico
      • Puebla City, Mexico
      • Tabasco, Mexico
      • Tijuana, Mexico
      • Veracruz, Mexico
  • Netherlands
      • Alkmaar, Netherlands
      • Amsterdam, Netherlands
      • Amsterdam-Zuidoost, Netherlands
      • Arnhem, Netherlands
      • Eindhoven, Netherlands
      • Groningen, Netherlands
      • Leiden, Netherlands
      • Maastricht, Netherlands
      • Nijmegen, Netherlands
      • Rotterdam, Netherlands
      • The Hague, Netherlands
      • Tilburg, Netherlands
      • Utrecht, Netherlands
  • Puerto Rico
      • San Juan, Puerto Rico
  • Russia
      • Kazan', Russia
      • Moscow, Russia
      • Oryol, Russia
      • Saint Petersburg, Russia
      • Smolensk, Russia
      • Volgograd, Russia
  • South Korea
      • Kyungki, South Korea
      • Pusan, South Korea
      • Seoul, South Korea
  • Spain
      • A Coruña, Spain
      • Alicante, Spain
      • Barakaldo Vizcaya, Spain
      • Barcelona, Spain
      • Bilbao, Spain
      • Cadiz, Spain
      • Cuenca, Spain
      • Córdoba, Spain
      • Donostia Guipuzcoa, Spain
      • Elche, Spain
      • Granada, Spain
      • Granollers, Spain
      • Logroño, Spain
      • Madrid, Spain
      • Murcia, Spain
      • Málaga, Spain
      • Oviedo, Spain
      • Palma de Mallorca, Spain
      • Pamplona, Spain
      • Sabadell, Spain
      • San Cristóbal de La Laguna, Spain
      • Santa Cruz de Tenerife, Spain
      • Santiago de Compostela (La Cor, Spain
      • Seville, Spain
      • Terrassa, Spain
      • Valencia, Spain
      • Vigo, Spain
      • Vitoria-Gasteiz, Spain
      • Zaragoza, Spain
  • Sweden
      • Gothenburg, Sweden
      • Malmö, Sweden
      • Stockholm, Sweden
  • Taiwan
      • Kaohsiung City, Taiwan
      • Taichung, Taiwan
      • Tainan, Taiwan
      • Taipei, Taiwan
  • Turkey (Türkiye)
      • Ankara, Turkey (Türkiye)
  • United States
    • Alabama
      • Anniston, Alabama, United States
      • Birmingham, Alabama, United States
    • Arizona
      • Flagstaff, Arizona, United States
      • Phoenix, Arizona, United States
      • Tucson, Arizona, United States
    • Arkansas
      • Little Rock, Arkansas, United States
    • California
      • Anaheim, California, United States
      • Arcata, California, United States
      • Bakersfield, California, United States
      • Baldwin Park, California, United States
      • Bellflower, California, United States
      • Beverly Hills, California, United States
      • Fontana, California, United States
      • Fountain Valley, California, United States
      • Fremont, California, United States
      • Garden Grove, California, United States
      • Glendale, California, United States
      • Harbor City, California, United States
      • Hayward, California, United States
      • Loma Linda, California, United States
      • Long Beach, California, United States
      • Los Angeles, California, United States
      • Newport Beach, California, United States
      • Oakland, California, United States
      • Palm Springs, California, United States
      • Palo Alto, California, United States
      • Panorama City, California, United States
      • Pasadena, California, United States
      • Pico Rivera, California, United States
      • Richmond, California, United States
      • Sacramento, California, United States
      • San Bernardino, California, United States
      • San Diego, California, United States
      • San Francisco, California, United States
      • San Mateo, California, United States
      • San Rafael, California, United States
      • Santa Ana, California, United States
      • Santa Clara, California, United States
      • Santa Clarita, California, United States
      • Santa Rosa, California, United States
      • Stanford, California, United States
      • Tarzana, California, United States
      • Ukiah, California, United States
      • Ventura, California, United States
      • Woodland Hills, California, United States
    • Colorado
      • Denver, Colorado, United States
      • Wheat Ridge, Colorado, United States
    • Connecticut
      • Glastonbury, Connecticut, United States
      • Hartford, Connecticut, United States
      • New Haven, Connecticut, United States
      • Norwalk, Connecticut, United States
      • Norwich, Connecticut, United States
    • District of Columbia
      • Washington D.C., District of Columbia, United States
    • Florida
      • Daytona Beach, Florida, United States
      • Fort Lauderdale, Florida, United States
      • Hollywood, Florida, United States
      • Jacksonville, Florida, United States
      • LaBelle, Florida, United States
      • Leesburg, Florida, United States
      • Miami, Florida, United States
      • Miami Beach, Florida, United States
      • North Miami Beach, Florida, United States
      • North Palm Beach, Florida, United States
      • Oakland Park, Florida, United States
      • Orlando, Florida, United States
      • Pensacola, Florida, United States
      • Plantation, Florida, United States
      • Port Saint Lucie, Florida, United States
      • Safety Harbor, Florida, United States
      • Sarasota, Florida, United States
      • Tampa, Florida, United States
      • Tarpon Springs, Florida, United States
      • Vero Beach, Florida, United States
      • West Palm Beach, Florida, United States
      • Weston, Florida, United States
      • Winter Park, Florida, United States
    • Georgia
      • Atlanta, Georgia, United States
      • Decatur, Georgia, United States
      • Jesup, Georgia, United States
      • Macon, Georgia, United States
      • Riverdale, Georgia, United States
      • Savannah, Georgia, United States
      • Tucker, Georgia, United States
    • Hawaii
      • Honolulu, Hawaii, United States
    • Idaho
      • Boise, Idaho, United States
    • Illinois
      • Aurora, Illinois, United States
      • Chicago, Illinois, United States
      • Joliet, Illinois, United States
      • Maywood, Illinois, United States
    • Indiana
      • Indianapolis, Indiana, United States
    • Iowa
      • Des Moines, Iowa, United States
      • Iowa City, Iowa, United States
    • Kentucky
      • Henderson, Kentucky, United States
      • Paducah, Kentucky, United States
    • Louisiana
      • New Orleans, Louisiana, United States
    • Maine
      • Ellsworth, Maine, United States
      • Portland, Maine, United States
    • Maryland
      • Baltimore, Maryland, United States
      • Greenbelt, Maryland, United States
      • Silver Spring, Maryland, United States
    • Massachusetts
      • Boston, Massachusetts, United States
      • Springfield, Massachusetts, United States
    • Michigan
      • Ann Arbor, Michigan, United States
      • Berkley, Michigan, United States
      • Detroit, Michigan, United States
      • Grand Rapids, Michigan, United States
      • Grosse Pointe Woods, Michigan, United States
      • Lansing, Michigan, United States
    • Minnesota
      • Minneapolis, Minnesota, United States
      • Rochester, Minnesota, United States
      • Saint Louis Park, Minnesota, United States
    • Missouri
      • Kansas City, Missouri, United States
      • St Louis, Missouri, United States
    • Nebraska
      • Lincoln, Nebraska, United States
    • Nevada
      • Las Vegas, Nevada, United States
    • New Hampshire
      • Rochester, New Hampshire, United States
    • New Jersey
      • Englewood, New Jersey, United States
      • Hackensack, New Jersey, United States
      • Long Branch, New Jersey, United States
      • Neptune City, New Jersey, United States
      • Newark, New Jersey, United States
      • Perth Amboy, New Jersey, United States
      • Somers Point, New Jersey, United States
      • Union, New Jersey, United States
      • Voorhees Township, New Jersey, United States
      • Westfield, New Jersey, United States
    • New Mexico
      • Santa Fe, New Mexico, United States
    • New York
      • Albany, New York, United States
      • Briarcliff Manor, New York, United States
      • Brooklyn, New York, United States
      • Buffalo, New York, United States
      • East Meadow, New York, United States
      • Elmira, New York, United States
      • Flushing, New York, United States
      • Kingston, New York, United States
      • Manhasset, New York, United States
      • Mount Vernon, New York, United States
      • New York, New York, United States
      • Rochester, New York, United States
      • Staten Island, New York, United States
      • The Bronx, New York, United States
    • North Carolina
      • Chapel Hill, North Carolina, United States
      • Gastonia, North Carolina, United States
      • Huntersville, North Carolina, United States
      • Winston-Salem, North Carolina, United States
    • Ohio
      • Akron, Ohio, United States
      • Cleveland, Ohio, United States
      • Columbus, Ohio, United States
      • Dayton, Ohio, United States
    • Oregon
      • Portland, Oregon, United States
    • Pennsylvania
      • Allentown, Pennsylvania, United States
      • Johnstown, Pennsylvania, United States
      • Philadelphia, Pennsylvania, United States
      • Pittsburgh, Pennsylvania, United States
    • Rhode Island
      • Providence, Rhode Island, United States
    • South Carolina
      • Charleston, South Carolina, United States
      • Columbia, South Carolina, United States
    • Tennessee
      • Johnson City, Tennessee, United States
      • Nashville, Tennessee, United States
    • Texas
      • Austin, Texas, United States
      • Bellaire, Texas, United States
      • Dallas, Texas, United States
      • El Paso, Texas, United States
      • Fort Worth, Texas, United States
      • Harlingen, Texas, United States
      • Houston, Texas, United States
      • Longview, Texas, United States
      • San Antonio, Texas, United States
    • Virginia
      • Annandale, Virginia, United States
      • Charlottesville, Virginia, United States
      • Fairfax, Virginia, United States
      • Hampton, Virginia, United States
      • Norfolk, Virginia, United States
      • Richmond, Virginia, United States
    • Washington
      • Olympia, Washington, United States
      • Seattle, Washington, United States
      • Spokane, Washington, United States
      • Yakima, Washington, United States
    • West Virginia
      • Charleston, West Virginia, United States
    • Wisconsin
      • La Crosse, Wisconsin, United States
      • Madison, Wisconsin, United States
      • Milwaukee, Wisconsin, United States

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Patient is at least 3-class experienced (3 classes of licensed oral antiretrovirals: nucleoside/tide reverse transcriptase inhibitors [N[t]RTI], protease inhibitors [PI], non-nucleoside reverse transcriptase inhibitors [NNRTI])
  • Patients with primary NNRTI resistance can be included if they are experienced with at least 2 classes of ARVs (PIs, N[t]RTIs) and meet all the other inclusion criteria
  • Patient has previously received 2 different PI-based regimens
  • Patient is unable to use currently approved NNRTIs due to resistance (primary or acquired) and/or intolerance
  • Patient, if currently receiving an ARV regimen, is not achieving adequate virologic suppression on his/her current regimen.

Exclusion Criteria:

  • Prior or current participation in DUET trials (TMC125-C206 or TMC125-C216).
  • Use of disallowed concomitant therapy, including disallowed antiretrovirals (ARV)
  • Use of investigational ARVs (with exceptions)
  • Any active clinically significant disease (e.g., cardiac dysfunction, pancreatitis, acute viral infection) or findings during screening of medical history or physical examination that is not either resolved or stabilized for at least 30 days before the Screening Phase
  • Pregnant or breast-feeding female
  • Female patient of childbearing potential not using effective non-hormonal birth control methods
  • Patients with specific laboratory abnormalities
  • Patients with clinical or laboratory evidence of significantly decreased hepatic function or decompensation.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: TMC125
TMC125 200 mg b.i.d. till commercially available.
Drug: TMC125
200 mg b.i.d. till commercially available.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Time Frame
The primary objective of TMC125-C214 is to provide early access to TMC125 for treatment-experienced HIV-1 infected patients who have failed multiple antiretroviral (ARV) regimens and have limited treatment options with currently approved ARVs.
Time Frame: pregnancy, discontinuation of TMC125 development or when TMC125 has become commercially available in the patient's country.
pregnancy, discontinuation of TMC125 development or when TMC125 has become commercially available in the patient's country.

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Time Frame
The secondary objective of this trial is to gather information on the safety and tolerability aspects of TMC125 in combination with other ARVs. Available efficacy data will also be collected.
Time Frame: pregnancy, discontinuation of TMC125 development or when TMC125 has become commercially available in the patient's country.
pregnancy, discontinuation of TMC125 development or when TMC125 has become commercially available in the patient's country.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Tibotec Pharmaceuticals, Ireland

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Study Director: Tibotec Pharmaceuticals Clinical Trial, Tibotec Pharmaceutical Limited

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
January 1, 2006

Primary Completion

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
February 1, 2012

Study Completion

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
March 1, 2012

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
July 18, 2006

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
July 18, 2006

First Posted (Estimated)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
July 20, 2006

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
June 4, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
June 2, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
June 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • CR002743
  • TMC125-C214 (Other Identifier: Tibotec Pharmaceuticals, Ireland)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings